284 related articles for article (PubMed ID: 15805578)
1. Introduction to the background, principles, and state of the art in suicide gene therapy.
Niculescu-Duvaz I; Springer CJ
Mol Biotechnol; 2005 May; 30(1):71-88. PubMed ID: 15805578
[TBL] [Abstract][Full Text] [Related]
2. Viral vectors for gene-directed enzyme prodrug therapy.
Schepelmann S; Springer CJ
Curr Gene Ther; 2006 Dec; 6(6):647-70. PubMed ID: 17168697
[TBL] [Abstract][Full Text] [Related]
3. Design of prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Springer CJ
Methods Mol Med; 2004; 90():161-202. PubMed ID: 14657564
[No Abstract] [Full Text] [Related]
4. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?
Nawa A; Tanino T; Luo C; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Nishiyama Y; Kikkawa F
Anticancer Agents Med Chem; 2008 Feb; 8(2):232-9. PubMed ID: 18288924
[TBL] [Abstract][Full Text] [Related]
5. Introduction to the background, principles, and state of the art in suicide gene therapy.
Niculescu-Duvaz I; Springer CJ
Methods Mol Med; 2004; 90():1-27. PubMed ID: 14657556
[No Abstract] [Full Text] [Related]
6. Progress and problems with the use of suicide genes for targeted cancer therapy.
Karjoo Z; Chen X; Hatefi A
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):113-128. PubMed ID: 26004498
[TBL] [Abstract][Full Text] [Related]
7. From bench to bedside for gene-directed enzyme prodrug therapy of cancer.
Dachs GU; Tupper J; Tozer GM
Anticancer Drugs; 2005 Apr; 16(4):349-59. PubMed ID: 15746571
[TBL] [Abstract][Full Text] [Related]
8. Suicide genes for cancer therapy.
Portsmouth D; Hlavaty J; Renner M
Mol Aspects Med; 2007 Feb; 28(1):4-41. PubMed ID: 17306358
[TBL] [Abstract][Full Text] [Related]
9. Prodrugs in genetic chemoradiotherapy.
Patterson AV; Saunders MP; Greco O
Curr Pharm Des; 2003; 9(26):2131-54. PubMed ID: 14529410
[TBL] [Abstract][Full Text] [Related]
10. Gene-directed enzyme prodrug therapy.
Zhang J; Kale V; Chen M
AAPS J; 2015 Jan; 17(1):102-10. PubMed ID: 25338741
[TBL] [Abstract][Full Text] [Related]
11. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.
Hedley D; Ogilvie L; Springer C
Nat Rev Cancer; 2007 Nov; 7(11):870-9. PubMed ID: 17943135
[TBL] [Abstract][Full Text] [Related]
12. Advances in imaging gene-directed enzyme prodrug therapy.
Bhaumik S
Curr Pharm Biotechnol; 2011 Apr; 12(4):497-507. PubMed ID: 21342105
[TBL] [Abstract][Full Text] [Related]
13. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors.
Amara I; Touati W; Beaune P; de Waziers I
Biochimie; 2014 Oct; 105():4-11. PubMed ID: 24977933
[TBL] [Abstract][Full Text] [Related]
16. Targeted enzyme prodrug therapies.
Schellmann N; Deckert PM; Bachran D; Fuchs H; Bachran C
Mini Rev Med Chem; 2010 Sep; 10(10):887-904. PubMed ID: 20560876
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
[TBL] [Abstract][Full Text] [Related]
18. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.
Alekseenko I; Kuzmich A; Kondratyeva L; Kondratieva S; Pleshkan V; Sverdlov E
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502287
[TBL] [Abstract][Full Text] [Related]
19. Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations.
Niculescu-Duvaz I; Springer CJ
Expert Opin Investig Drugs; 1997 Jun; 6(6):685-703. PubMed ID: 15989636
[TBL] [Abstract][Full Text] [Related]
20. Prodrug cancer gene therapy.
Altaner C
Cancer Lett; 2008 Nov; 270(2):191-201. PubMed ID: 18502571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
